Vioxx Litigation May Freeze Class-Wide Drug Development, AEI Scholar Calfee Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Former FDA Chief Counsel Troy says Merck’s strategy to defend each case independently may backfire.